Background {#Sec1}
==========

Doxorubicin (DOX) is an anthracycline derivative, clinically efficacious antitumor drug in the management of solid tumors and leukemia. Despite the wide range of anticancer efficiency, DOX leads to varied side effects, including cardiomyopathy, renal, hepatic, pulmonary, testicular and hematological toxicities \[[@CR1]--[@CR3]\]. Despite the fact that cardiotoxicity is a preferential target of DOX treatment its harmful effects are also obvious in different organs comprising liver, renal tissue, and brain \[[@CR4]--[@CR6]\]. The liver is the chief detoxifying tissue; therefore it is the target of excessive amounts of genotoxic composites and anticancer drugs including doxorubicin. Approximately 40% of patients on doxorubicin suffer from liver injury. DOX elicit severe consequences due to the presence of quinone moiety in the anthracycline ring structure, which is involved in both oxidative and reductive biotransformation's and finally resulting in the generation of highly reactive substances predisposed for oxidative stress. DOX persuaded hepatotoxicity includes hepatic cell cycle arrest, free radical generated oxidative stress triggered by hepatic expression of genes intricate in oxidative distress reactions, DNA repair, cell cycle progression and cell death \[[@CR7]\]. But the accurate cause bringing up the hepatotoxic influence of DOX is not completely clarified. To preclude the inimical effects of DOX many pharmacologic agents, i.e., hematopoietic cytokines and iron chelating drugs were used \[[@CR8], [@CR9]\]. The improvement of DOX analogues and the assembly of effective delivery techniques are also operative ways to counter its side effects. In spite of their favorable outcomes, some of these procedures failed to neutralize DOX toxicity in clinical prosecutions. Mounting evidence suggest that a concurrent usage of chemotherapy and with natural antioxidants may amplify the effectiveness of chemotherapeutic \[[@CR10], [@CR11]\]. Consequently, it is obligatory to explore more effective strategies against DOX-induced complications while preserving or enhancing its therapeutic effects. Seeking for impeccable protection to counter free radical mediated injury is stayed an immense scientific challenge. It is clear that varied natural products own prevailing aptitude to contravene the harmfulness of DOX and other anthracycline antibiotics. Flavonoids are naturally existing constituents that attain varied pharmacological possessions and curative implications. The beneficial influences are validated to their phenolic structures which own antioxidant efficacy and restrain free radical-facilitated reactions. Treatment with medicinal plants is considered a usual practice implemented in traditional and alternative medicine that has been effective in the cure of many diseases from ancient times \[[@CR12]\].

*Acacia* species possess diverse medicinal properties and have come under extensive investigation in light of their antioxidant, antimutagenic and anticarcinogenic effects \[[@CR13]\]. *Acacia hydaspica* R. Parker synonym *Acacia eburnea*; family Leguminosae is the pharmacologically important plant. The vernacular name of the plant is Pahari Kikar, Kikar; Marmat. The bark and seeds are rich in tannins \[[@CR14], [@CR15]\]. *A. hydaspica* has antioxidant, anticancer \[[@CR16]\], anti-inflammatory \[[@CR17]\], antidepressant \[[@CR18]\], cardioprotective against DOX induced cardiotoxicity \[[@CR19]\], protective against CP induced reproductive, and hepatic toxicity \[[@CR20], [@CR21]\]. GCMS analysis identified 1, 2-benzenedicarboxylic acid mono (2-ethylhexyl) ester (70.65%), α-amyrin (5.03%), vitamin E (4.56%), 2,6-dimethyl-N-(2-methyl-à-phenylbenzyl) aniline (2.51%) and squalene (4%) in *A. hydaspica* \[[@CR18]\]. Bioassay guided isolation identified as 7-*O*-galloyl catechin, catechin, catechin gallate and methyl gallate as major antioxidant and anticancer compounds from *A. hydaspica* ethyl acetate fraction (AHE) \[[@CR16], [@CR22], [@CR23]\]. Various species of genus *Acacia* were explored for their antioxidant and hepatoprotective proficiencies in animal models. *Acacia nilotica* (L.) showed protection against acetaminophen-prompted hepatocellular injury in rats by ameliorating aspartate transaminase (AST), alkaline phosphatase (ALP), alanine transaminase (ALT), total bilirubin, total protein, and lipid peroxidation, while augmenting antioxidant parameters. Morphological examination also authenticates the protective effect of *A. nilotica* against acetaminophen provoked hepatic damage \[[@CR24]\]. An ethanol extract of *A. nilotica* bark exhibited hepatoprotective outcome against Isoniazid-INH and rifampicin-RIF prompted liver injury. Biochemical aspects such as serum glutamate oxaloacetate transaminase (SGOT), serum glutamate pyruvate transaminase (SGPT), ALP, total bilirubin and the histoarchitecture of the liver also validated its hepato-protective action (Verma et al., 2014). Likewise, pretreatment with ethyl acetate extract of *Acacia catechu* certainly dissuaded CCl4 persuaded fluctuations in the biochemical enzyme levels and liver morphology. The effects of *Acacia catechu* were comparable to that of the standard drug silymarin \[[@CR25]\]. *Acacia ferruginea* ethanol significantly decreased CCL~4~ induced increase in the level of ALT, AST, total bilirubin and direct bilirubin in the blood. The presence of active phytoconstituents i.e., flavonoids and tannins may be predisposed for hepatic-protection \[[@CR26]\]. Nonetheless, to the best of our knowledge, there is a study demonstrating the antioxidant and hepatic-protective potential of *Acacia species* against DOX induced liver injury.

Based on hepatic-protective efficacy of other *Acacia* species in animal models of liver injury and varied biological properties of *A. hydaspica*, in current research, we aimed to study its hepatic-protective activity against the DOX-induced liver injury. The effect of AHE on the antioxidant status, biochemical alterations, and histoarchitecture in DOX-induced hepatotoxicity was studied by lipid profile analysis, liver function tests in serum, antioxidant enzymes and oxidative stress markers in liver tissue along with histopathological examinations.

Methods {#Sec2}
=======

Plant collection and extract preparation {#Sec3}
----------------------------------------

Aerial parts of *A. hydaspica* were collected from Kirpa charah area Islamabad, Pakistan. Plant specimen was identified by Dr. Sumaira Sahreen (Curator at Herbarium of Pakistan, Museum of Natural History, Islamabad). Plant specimen with Accession No. 0642531 was deposited in the Herbarium of Pakistan, Museum of Natural History, Islamabad. *A. hydaspica* methanol extract was fractionated as previously described \[[@CR17]\], and its ethyl acetate extract (AHE) (the most bioactive extract under in vitro and in vivo examinations and containing bioactive polyphenols \[[@CR17], [@CR19], [@CR23]\]) was tested in current investigation.

Dose preparation {#Sec4}
----------------

Doxorubicin (DOX) injections were obtained from Sigma-Aldrich (St. Louis, MO, U.S.A.) and dissolved in saline to make an appropriate dose for administration. An entire doxorubicin dose of 18 mg/kg body weight was inoculated to rats during the experimental period \[[@CR6]\]. Silymarin and AHE were freshly prepared in distilled water before dosing \[[@CR27]\].

Scheme of experiment {#Sec5}
--------------------

Animals were adapted to the laboratory environment for 1 week. Thirty six male Sprague Dawley rats (200--225 g) were randomly separated into six groups *(n* = 6) and placed in individual cages. The study procedure was planned according to earlier studies \[[@CR28]--[@CR30]\] with slight modifications.Group 1: Control group administered normal saline for 6 weeks (one dose/week, 0.4 ml, i.p.)Group II: Drug control was inoculated with DOX (i.p, 3 mg/kg b.w.) for 6 weeks (1 dose week, so total dose was18 mg/kg b.w.).Group III: Plant control group was treated with a single oral dosage of AHE (400 mg/kg b.w.) daily for 6 weeks.Group IV: DOX + AHE 200 mg/kg; treated with a single oral dose of AHE (200 mg/kg b.w) daily for 6 weeks along with DOX inoculation once per week.Group V: DOX + AHE 400 mg/kg; treated with oral doses of AHE (200 mg/kg b.w) for 6 weeks with in conjunction with DOX inoculation once per week.Group VI: DOX + Silymarin; received 2 oral doses of Silymarin 100 mg/kg b.w/ week (12 doses/6 weeks) in conjunction with DOX inoculation once per week. Body weights of rats were recorded at the start and end of the experiment.

Twenty-four hour after last treatment rats were euthanized by cervical dislocation and dissected from the ventral side. Blood samples were drawn through a direct intra-cardiac puncture and poured in sterile labeled tubes and submitted to centrifugation at 10,000 rpm for 15 min at 4 °C to obtain serum. Serum samples were placed in a freezer at − 80 °C for following biochemical analysis. After taking blood, the liver was excised and cleaned with ice cold normal saline, blotted with filter paper and weighed.

The liver index was determined by the formula: $\documentclass[12pt]{minimal}
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Next, a partial portion of liver was treated with liquid nitrogen and preserved at − 80 °C for further biochemical examinations, while the other half was placed in buffered formalin for histological processing.

Liver function test and lipid profile {#Sec6}
-------------------------------------

Liver function tests such as aspartate aminotransferase (AST), alkaline phosphatase (ALP), alanine aminotransferase (ALT), lactate dehydrogenase (LDH) were measured in serum. Furthermore, the amount of total cholesterol (TC), high-density lipoproteins (HDL), low-density lipoproteins (LDL) and triglycerides (TG) were approximated by using standard AMP diagnostic kits (Stattogger Strasse 31b 8045 Graz, Austria).

Biochemical examination {#Sec7}
-----------------------

### Homogenate preparation {#Sec8}

Hepatic tissues (100 mg) were homogenized in KH~2~PO~4~ buffer (100 mM) containing EDTA (1 mM, pH 7.4). The homogenate was centrifuged at 12000×g for 30 min at 4 °C and the supernatant was stored in aliquots at - 20 °C for examining antioxidant enzymes and oxidative stress markers.

### Assessment of total protein {#Sec9}

Total soluble proteins in hepatic tissues were calculated by Lowry et al. procedure \[[@CR31]\]. Bovine serum albumin (BSA) standard calibration curve was used to find out the concentration of proteins in the sample.

Valuation of tissue antioxidant status {#Sec10}
--------------------------------------

### Catalase (CAT) activity {#Sec11}

CAT activity was calculated as earlier established procedure \[[@CR19]\]. An absorbance change of 0.01 as units/min symbolizes one unit of catalase activity.

### Peroxidase (POD) activity {#Sec12}

POD activity was detected by earlier established decorum \[[@CR19]\]. One unit POD activity is correspondent to variation in absorbance of 0.01 as units/min.

### Superoxide dismutase (SOD) activity {#Sec13}

Measurement of SOD level in hepatic tissue was performed by Kakkar et al. method \[[@CR32]\]. Results were calculated in units/mg protein.

### Quinone reductase assay (QR) {#Sec14}

The Quinone reductase level in hepatic tissues of different treatment groups was measured as described formerly \[[@CR33]\]. Enzyme quantity was estimated as nM of DCPIP reduced/min/mg protein by employing molar extinction coefficient of 2.1 × 10^4^/M/cm.

### Reduced glutathione (GSH) estimation test {#Sec15}

Reduced glutathione activity was checked as described by Jollow \[[@CR34]\]. The GSH activity was measured by μM GSH/g tissue.

### Glutathione-S-transferase (GST) {#Sec16}

Assessment of GST potency was done as described before \[[@CR19]\]. GST activity was calculated as amount of CDNB conjugate formed per minute per mg protein using molar coefficient of 9.61 × 10^3^/M/cm.

### Glutathione reductase assay (GR) {#Sec17}

Glutathione reductase activity in tissue samples was evaluated as described by Carlberg and Mannervik \[[@CR35]\]. Enzyme level measured as nM NADPH oxidized/min/mg protein by employing molar extinction coefficient of 6.22 × 10^3^/M/cm.

### Glutathione peroxidase assay (GPx) {#Sec18}

Glutathione peroxidase activity was measured as presented elsewhere \[[@CR36]\]. Enzyme level was estimated as nM NADPH oxidized/min/mg protein employing 6.22 × 10^3^/M/cm molar extinction coefficient.

### γ-Glutamyl transpeptidase (γ-GT) {#Sec19}

The activity of γ-glutamyl transpeptidase was checked following Orlowski et al. scheme \[[@CR37]\]. Activity of γ-GT was determined as nM nitroaniline formed per min per mg protein by the aid of molar extinction coefficient of 1.75 × 10^3^/M/cm.

Measurement of oxidative stress markers in liver {#Sec20}
------------------------------------------------

### Lipid peroxidation assay (TBARs/LPO) {#Sec21}

Protocol of Sehreen et al. \[[@CR38]\] was adopted with slight modifications for the assessment of lipid peroxidation. By exploiting the molar extinction coefficient of 1.56 × 10^5^/M/cm results were estimated as nM of TBARS generates per min per mg tissue at a temperature of 37 °C.

### Hydrogen peroxide assay {#Sec22}

Estimation of hydrogen peroxide activity in tissue samples was monitored by method described earlier \[[@CR39]\]. Production of H~2~O~2~ was measured as nM H~2~O~2~/min/mg tissue by employing the standard curve of phenol red oxidized by H~2~O~2~.

### Nitrite assay {#Sec23}

Griess reagent was used for the performance of nitrite assay \[[@CR40]\]. Standard curve of sodium nitrite was employed for the calculation of nitrite levels in hepatic tissues.

Histoarchitecture examination {#Sec24}
-----------------------------

For morphological analysis, hepatic tissue samples from each group were fixed in a fixative made of absolute alcohol (85 ml), glacial acetic acid (5 ml) and 40% formaldehyde (10 ml). After dehydration tissue samples were fixed in paraffin to prepare blocks for microtomy. Tissues were sectioned 4--5 μm with microtome and stained with Hemotoxilin-Eosin (H&E) and studied under a light microscope (DIALUX 20 EB) at 40X. Photographs were taken with same the zoom and the camera settings were used and histological parameters were analyzed.

Statistical analysis {#Sec25}
--------------------

Data are resented as mean ± SEM (*n* = 6). For analyzing the statistical differences between different treatment groups one way analysis of variance (ANOVA) followed by Tukey's test was used using Graph pad prism 5 software. Level of significance was set at *p* \< 0.05.

Results {#Sec26}
=======

AHE usage is not linked with injuriousness {#Sec27}
------------------------------------------

No clinical indication of injuriousness for instance infrequent salivation, flicking gestures, shivering, incoordination, head and forelimb clonuses, convulsions, diarrhea and raised diuresis were seen in any treatment group. No casualty was detected in either treatment group throughout the investigation period. AHE treatment group displayed comparable body weight gain as the control group (Fig. [1](#Fig1){ref-type="fig"}a). Likewise, no change in liver weight was recorded in AHE and control groups (Fig. [1](#Fig1){ref-type="fig"}b), implying a nontoxic effect of AHE dosage. The hepatic tissues from either control or AHE treated rats revealed no detectable alterations in histo-architecture (Fig. [3](#Fig3){ref-type="fig"}; group 1 and 3).Fig. 1Effect of the ethyl acetate extract of *A. hydaspica (AHE)* on **a** body weight, **b** liver weight and **c** liver index (%) in various treatment groups. Mean ± SE (*n* = 6); statistical symbols in **a** indicated significant difference in final vs initial body weight; in **b** and **c** ^\*,\ \*\*,\ \*\*\*^ indicated significance from the control group at *p* \< 0.05, *p* \< 0.001 and *p* \< 0.0001 probability level, ^+,\ ++,\ +++^ indicate significance from the DOX group at *p* \< 0.05, *p* \< 0.01 and *p \<* 0.0001 while ^\#\#,\ \#\#\#^ indicate significance of AHE 400 mg kg bw treatment vs AHE 200 mg kg bw treatment group at *p* \< 0.001 and *p \<* 0.0001 probability level respectively (One way ANOVA followed by Tukey's multiple comparison tests)

Body weight and liver index {#Sec28}
---------------------------

In the course of 6 week experiment duration DOX-inoculation caused a significant reduction (*p* \< 0.0001) in body weight while increased the absolute and relative liver weight (liver index) in contrast to the controls (Fig. [1](#Fig1){ref-type="fig"}a). Co-treatment with AHE maximally secured growth-slow down the effect of DOX in a dose dependent manner (DOX + AHE 400 mg/kg b.w. vs. DOX, *p* \< 0.001; DOX + AHE 200 mg/kg b.w. vs. DOX, *p* \< 0.001). These results indicated that AHE alienate the undesirable effect of DOX on body weight and liver weight (Fig. [1](#Fig1){ref-type="fig"}a, b & c). AHE 400 mg dose showed comparable effect as silymarin treated animals.

Effect of AHE on serum liver function tests (LFTs) {#Sec29}
--------------------------------------------------

DOX-administration results in significant (*p* \< 0.0001) upsurge in ALT, AST, ALP and LDH levels, hence confirming the liver damage at the cellular level. Moreover, TB and DB concentrations were also significantly elevated (*p* \< 0.0001) in DOX-administered animals compared to control group. Treatment with AHE magnificently ameliorated the elevated activities of LFTs, TB and DB in a concentration dependent manner. Serum enzyme activities in AHE 400 mg/kg b.w group were ameliorated correspondingly to silymarin treated group. AHE lone at 400 mg/kg b.w. showed no alteration in enzyme levels when compared to control (Table [1](#Tab1){ref-type="table"}).Table 1Effect of Doxorubicin (DOX) and different treatments of AHE on Liver Function tests (LFTs)Treatment (mg/kg)ALT (U/l)AST (U/l)ALP (U/l)LDH (U/l)Total bilirubin (TB mg/dl)Direct bilirubin (DB mg/dl)Control44.63 ± 0.491^b^72.83 ± 0.120^b^120.7 ± 0.333^b^48.62 ± 0.232 ^b^0.92 ± 0.015^b^0.303 ± 0.037^b^DOX139.80 ± 0.336^a^191.0 ± 0.577^a^355.8 ± 0.120^a^171.10 ± 0.358 ^a^1.84 ± 0.016^a^0.546 ± 0.017^a^AHE alone44.57 ± 0.233^b^72.63 ± 0.186^b^120.7 ± 0.208^b^48.57 ± 0.203 ^b^0.917 ± 0.013^b^0.300 ± 0.036^b^DOX + AHE (200)79.62 ± 0.523^a,\ b,\ d^135.9 ± 0.133^a,\ b,\ d^211.2 ± 0.441^a,\ b,\ d^98.97 ± 0.548^a,\ b,\ d^1.45 ± 0.023^a,\ b,\ d^0.443 ± 0.009^a\*^DOX + AHE (400)47.27 ± 0.318^a\*\*,\ b,\ c^76.83 ± 0.167^a,\ b,\ c^134.8 ± 0.338^a,\ b,\ c^60.37 ± 0.578^a,\ b,\ c^1.193 ± 0.012^a,\ b,\ c^0.348 ± 0.024^b\*\*^DOX + Sily46.47 ± 0.176^a\*,\ b^76.13 ± 0.133^a,\ b^133.1 ± 0.591^a,\ b^58.67 ± 0.333 ^a,\ b^1.18 ± 0.015^a,\ b^0.345 ± 0.020^b\*\*^Values expressed as mean ± SEM. ^a^ Significance at *p* \< 0.0001 Vs. control group, ^b^ Significance at *p* \< 0.0001 Vs. Doxorubicin (DOX) group, ^c^ Significance at *p* \< 0.0001 of DOX + AHE 400 mg/kg group Vs. DOX + AHE 200 mg/kg group. ^d^ Significance at *p* \< 0.0001 of AHE co-treatment groups Vs DOX + Sily group. ^\*,\ \*\*^ Significant difference at *p* \< 0.05 and *p* \< 0.001 respectively. Non-significant difference (*p* \> 0.05) was recorded between control and AHE alone treated group in all parameters. (One way ANOVA followed by Tukey's multiple comparison tests). Sily-Silymarin

Lipid profile {#Sec30}
-------------

Hepatotoxins react with polyunsaturated fatty acids to persuade lipid peroxidation by disturbing the lipid profile. DOX administration markedly (*P* \< 0.0001) increased the levels of total cholesterol, LDL and triglycerides, while decreasing (*P* \< 0.0001) HDL levels as compared to control group (Fig. [2](#Fig2){ref-type="fig"}a, b, c and d; respectively). Co administration of AHE with DOX, dose dependently ameliorated the altered lipid profile. Silymarin treated group showed similar protection against DOX induced lipid profile changes as shown by DOX + AHE 400 mg/kg group. Animals treated with AHE alone at 400 mg/kg.bw dose showed an insignificant difference in results compared to control group.Fig. 2Effect of DOX and different treatments of AHE on Lipid profile. **a** Serum Cholesterol, **b** Serum Triglycerides, **c** High density lipoproteins (HDL), **d** Low density lipoproteins(LDL). Values expressed as mean ± SEM. ^\*,\ \*\*,\ \*\*\*^ shows significance from control group at *p* \< 0.05, *p* \< 0.001, *p* \< 0.0001, ^++,\ +++^ shows significance from DOX group at *p* \< 0.001, *p* \< 0.0001. \#, \#\#\# shows significance from AHE 400 mg kg bw treatment vs AHE 200 mg kg bw treatment group respectively. Non-significant difference (*p* \> 0.05) was recorded between control and AHE alone treated group in all parameters (One way ANOVA followed by Tukey's multiple comparison tests)

Measurement of antioxidant enzymes {#Sec31}
----------------------------------

Liver oxidative stress and antioxidant defense parameters were evaluated to investigate the protective influence of AHE against DOX provoked deteriorations in liver tissue. DOX administration on alternate days for 6 weeks results in significant (*p* \< 0.0001) depletion in the quantity of POD, SOD, CAT and QR as compared to control group, while AHE alone showed no alterations in the enzyme activity when compared to control levels (Table [2](#Tab2){ref-type="table"}). Co-administration of AHE with DOX outcomes in noteworthy amelioration of antioxidant enzyme levels, and at high dose the above mention enzyme levels were statistically similar to the silymarin treated group.Table 2Effect of Doxorubicin (DOX) and different treatments of AHE on hepatic POD, SOD, CAT and QR statusTreatment (mg/kg)POD (U/min)SOD (U/mg protein)CAT (U/min)QR (nM/min/mg protein)Control13.40 ± 0.225^b^1.547 ± 0.0592^b^24.02 ± 0.077^b^104.8 ± 1.006^b^DOX6.090 ± 0.589^a^0.3824 ± 0.054^a^12.72 ± 0.044^a^64.79 ± 1.070^a^AHE alone13.09 ± 0.266^b^1.553 ± 0.0814^b^24.03 ± 0.026^b^104.7 ± 1.065^b^DOX + AHE (200)9.06 ± 0.271^a,\ b,\ d^1.063 ± 0.0364^a\*\*,\ b^15.43 ± 0.063^a,\ b,\ d^76.81 ± 0.476^a,\ b,\ d^DOX + AHE (400)12.09 ± 0.179^b,\ c^1.371 ± 0.0794^b,\ c\*^20.83 ± 0.058^a,\ b,\ c^94.87 ± 1.433^a,\ b,\ c^DOX + Sily12.20 ± 0.237^b^1.323 ± 0.0566^b^20.90 ± 0.088^a,\ b^93.40 ± 1.440^a,\ b^Values expressed as mean ± SEM. ^a^ Significance at *p* \< 0.0001 Vs. control group, ^b^ Significance at *p* \< 0.0001 Vs. Doxorubicin (DOX) group, ^c^ Significance at *p* \< 0.0001 of DOX + AHE 400 mg/kg group Vs. DOX + AHE 200 mg/kg group. ^d^ Significance at *p* \< 0.0001 of AHE co-treatment groups Vs DOX + Sily group. ^\*,\ \*\*^ Significant difference at *p* \< 0.05 and *p* \< 0.001 respectively. Non-significant difference (*p* \> 0.05) was recorded between control and AHE alone treated group in all parameters. (One way ANOVA followed by Tukey's multiple comparison tests). Sily-Silymarin

DOX-treatments led to noticeable (*p* \< 0.0001) depletion of hepatic phase II antioxidant enzymes (QR, GSH, GR, GST, γ-GT and GPx) compared with the control group (Table [3](#Tab3){ref-type="table"}). DOX induced deteriorations were significantly prevented by co-treatment of AHE dose dependently. Treatment of animals with AHE high dose (400 mg/kg b.w) in conjunction with DOX considerably reinstated the levels of these enzymes and insignificant difference in the activity of these antioxidant enzymes were recorded in comparison with silymarin treated group. Oral administration of AHE for 6 weeks revealed non-significant change in antioxidant enzymes activity when compared to control group indicating the non-toxic effect of the AHE extract.Table 3Effect of Doxorubicin (DOX) and different treatments of AHE on hepatic phase II antioxidant enzymes and GSH profileTreatment (mg/kg)GSH (μM/g tissue)GR (nM/min/mg protein)GST (nM/min/mg protein)γ-GT (nM/min/mg Protein)GPx (nM/min/mg Protein)Control19.61 ± 0.283^b^163.6 ± 0.656^b^142.6 ± 0.57^b^336.2 ± 0.564^b^139.5 ± 1.164^b^DOX10.46 ± 0.660^a^101.4 ± 0.599^a^99.72 ± 1.08^a^141.6 ± 0.296^a^92.58 ± 0.752^a^AHE alone20.11 ± 0.158^b^164.2 ± 0.677^b^142.7 ± 0.89^b^336.3 ± 0.999^b^139.8 ± 0.355^b^DOX + AHE (200)12.50 ± 0.397^a,\ d^134.8 ± 0.81^a,\ b,\ d^118.7 ± 1.81^a,\ b,\ d\*^199.2 ± 1.610^a,\ b,\ d^111.3 ± 0.874^a,\ b,\ d^DOX + AHE (400)17.43 ± 0.599^a\*,\ b,\ c^149.8 ± 0.91^a,\ b,\ c^130.8 ± 1.86^a\*\*,\ b,\ c\*\*^306.8 ± 0.779^a,\ b,\ c^130.5 ± 1.192^a,\ b,\ c^DOX + Sily17.32 ± 0.387^a\*,\ b^152.7 ± 1.671^a,\ b^128.3 ± 2.82^a,\ b^307.9 ± 1.246^a,\ b^130.9 ± 0.344^a,\ b^Values expressed as mean ± SEM. ^a^ Significance at *p* \< 0.0001 Vs. control group, ^b^ Significance at *p* \< 0.0001 Vs. Doxorubicin (DOX) group, ^c^ Significance at *p* \< 0.0001 of DOX + AHE 400 mg/kg group Vs. DOX + AHE 200 mg/kg group. ^d^ Significance at *p* \< 0.0001 of AHE co-treatment groups Vs DOX + Sily group. ^\*,\ \*\*^ Significant difference at *p* \< 0.05 and *p* \< 0.001 respectively. Non-significant difference (*p* \> 0.05) was recorded between control and AHE alone treated group in all parameters. (One way ANOVA followed by Tukey's multiple comparison tests). Sily-Silymarin

Measurement of oxidative stress in hepatic tissues {#Sec32}
--------------------------------------------------

ROS origination and lipid peroxidation have been verified to be responsible for DOX-provoked hepatic damage. Table [4](#Tab4){ref-type="table"} illustrates the influence of AHE treatment on the liver tissue protein, oxidative deterioration markers in normal and DOX-administered rats. Chronic treatment of DOX to rats exhibited significant (*p* \< 0.0001) reduction in tissue soluble protein content verses control group. Oral administration of AHE restores the protein content in DOX treated animals to the levels in the control group. Contrariwise, liver oxidative stress markers (H~2~O~2~ and NO) and products of lipid peroxidation (TBARs) were significantly raised up as a result of DOX treatment. Co-treatment with AHE significantly alleviates the DOX toxicity in a dose dependent manner. AHE administration to DOX treated rat led to decrease oxidative stress markers and decrease the process of lipid peroxidation in a pattern similar to experimental group that received only silymarin. These results indicate that AHE prevents oxidative stress and lipid peroxidation and increases the concentration of antioxidant enzymes.Table 4Effect of Doxorubicin (DOX) and different treatments of AHE on liver tissue protein content and oxidative stress markersTreatment (mg/kg)Protein (μg/mg Tissue)H~2~O~2~ (nM/min/mg Tissue)Nitrite (content μM/ml)TBARS (nM/min/mg protein)Control4.657 ± 0.047^b^1.969 ± 0.056^b^34.77 ± 1.323^b^3.499 ± 0.156^b^DOX1.150 ± 0.049^a^5.356 ± 0.074^a^90.65 ± 1.787^a^9.492 ± 0.427^a^AHE alone4.677 ± 0.149^b^1.321 ± 0.057^b^36.24 ± 0.958^b^3.153 ± 0.087^b^DOX + AHE (200)3.200 ± 0.232^a,\ b,\ d\*^4.039 ± 0.021^a,\ b,\ d^60.72 ± 2.577^a,\ b,\ d^6.240 ± 0.589^a,\ b^DOX + AHE (400)4.128 ± 0.195^b,\ c\*\*^2.319 ± 0.038^a\*\*,\ b,\ c^43.25 ± 0.485^a\*,\ b,\ c^4.446 ± 0.217^b,\ c\*^DOX + Sily3.985 ± 0.074^b^2.336 ± 0.062^a\*\*,\ b^41.32 ± 1.194^b^4.829 ± 0.067^b^Values expressed as mean ± SEM. ^a^ Significance at *p* \< 0.0001 Vs. control group, ^b^ Significance at *p* \< 0.0001 Vs. Doxorubicin (DOX) group, ^c^ Significance at *p* \< 0.0001 of DOX + AHE 400 mg/kg group Vs. DOX + AHE 200 mg/kg group. ^d^ Significance at *p* \< 0.0001 of AHE co-treatment groups Vs DOX + Sily group. ^\*,\ \*\*^ Significant difference at *p* \< 0.05 and *p* \< 0.001 respectively. Non-significant difference (*p* \> 0.05) was recorded between control and AHE alone treated group in all parameters. (One way ANOVA followed by Tukey's multiple comparison tests). Sily-Silymarin

Histopathology of liver {#Sec33}
-----------------------

Histopathological inspection of liver tissue revealed normal hepatocytes structure in the control (Fig. [3](#Fig3){ref-type="fig"}). DOX inoculation leads to hepatotoxicosis. DOX induced edema, tissue injury, and sinusoidal dilatation, mononuclear cell infiltration, degeneration in the hepatocytes as well as focal necrosis, cellular hypertrophy, steatosis, blood vessel congestion and septa formation. The austere liver damage persuaded by DOX was remarkably proscribed by co-treatment with AHE, with most prominent ameliorative effects observed in high dose treatment in which liver morphology was near to normal. In the AHE-low dose treatment group few inflammatory cells and congestion of central veins as hepatic sinusoids look like lined by endothelial cells. The liver in rats treated with AHE alone was nearly of control liver histology. The data suggest that AHE could counteract DOX persuaded hepatic damage. The lesions were reduced considerably in a group received silymarin with DOX and recovery pattern was similar to AHE high dose.Fig. 3Histopathological examination of rat liver (H&E staining magnification 40X). Group 1: Liver section from control rats showing normal liver morphology. Group 2: DOX-treated rat liver section showing enhanced cellular lesions, loss of hepatic tissue structure arrangement and collection of inflammatory cells. Group 3: Represents liver section from AHE alone treated rats. Group 4: AHE low dose treatment results in minimal degenerations were observed. Group 5: AHE high dose treatment results in significant protection against DOX induced hepatic injury. Group 6: Showed protective effect of Silymarin treatment. AHE-*A. hydaspica* ethyl acetate fraction, DOX-Doxorubicin, HPC-Hepatocytes, CV-Central venule, MCI-Monocytes nuclear cells infiltrations, D&C-Dilation and congestion, FC & B- Fatty changes and ballooning, DLS- Degeneration of lobular shape, S-Sinosides, N-necrosis

Discussion {#Sec34}
==========

Doxorubicin (DOX) is a potent anti-tumor drug against a broad range of malignancies. However, DOX use is restricted for its severe cardiotoxicity and hepatotoxicity \[[@CR41]\]. Compromised antioxidant defense system and oxidative stress induced generation of ROS are major alterations in DOX induced toxicity \[[@CR42]\]. Until now, extensive number of investigations have been focused on the ways of preventing the chemotherapy induced side effects using herbal products \[[@CR43]\]. These studies suggested that the side effects of DOX could be minimized by plant extracts of different chemical nature. We hypothesized that flavonoid rich AHE extract could be beneficial in attenuating drug-induced oxidative hepatic damage. Therefore, the effect of AHE was evaluated in dose dependent manner to study its protective effect against DOX induced hepatic toxicity.

In current investigation, DOX administration for 6 weeks (3 mg/kg b.w/week) outcomes in a substantial decline in the final body weight of rats in contrast to the control group. In accord with our observations, Raskovic and colleagues reported that DOX treatment has been associated with substantial decrease of body weight in rats \[[@CR41]\]. The decline in body weight gain might be in some manner due to the direct toxic impact of this chemotherapy drug on renal tubules that prompted lessening in water reabsorption and disproportionate sodium excretion ensuing dehydration, polyuria and fall in body weight \[[@CR44], [@CR45]\] or it might be due to gastrointestinal toxicity with consequent diminution in appetite, consumption and assimilation of food \[[@CR44]\]. In contrast, an observable improvement in the body weight was recorded in AHE administered animals. AHE co-treatment at 400 mg/kg dose restored the body weight and ameliorated organ weight adjacent to that of the control group.

In the present research, it was observed that DOX disturb liver function by alterations in the plasma lipoproteins. Changeable levels of plasma lipoproteins link with accurate liver functioning. Low density lipoproteins (LDL) and high density lipoproteins (HDL) are central in lipoprotein pathway. DOX induced hepatic fibrosis with high cholesterol, triglycerides, LDL and decreased the level of HDL. These alterations in lipid profile indicated an association with liver and heart ailments in people with DOX therapy. Hyperlipidemia appears to be the major factor contributes to adriamycin induced heart failure \[[@CR46]\]. Results showed significant amelioration of altered serum total cholesterol, triglycerides, LDL and HDL levels in AHE treatment groups, and AHE dose dependently replenish the alteration induced by DOX. These findings exhibit the hepato-protective effect of plant fraction. Presence of flavonoids in AHE might be responsible for the observed effect. The study of Pilehvar and coworkers indicated that flavonoid rich grape seed oil decrease the TG and cholesterol while increase the HDL content in male Wister rats \[[@CR47]\].

The higher levels of serum biomarkers in the DOX-alone treated group indicated serious toxicity, as a results of DOX accretion in the liver that might provoke cellular obliteration or increase the permeability of hepatic cells. Results showed marked liver impairments in DOX administered groups as revealed by significantly elevated levels of serum concentration of ALT, AST, ALP, TSB and DB. The high level of serum biomarkers is an affirmation of hepatic dysfunction, which could be subsidiary incident subsequent to drug-prompted liver damage with enzyme seepage from the hepatocytes. Similarly Zhao and colleagues demonstrated the hepatotoxic effect of DOX by altering serum AST and ALT activities and inducing oxidative stress \[[@CR6]\]. AHE secure cellular injury by curtailing levels of serum biomarkers due to the presence of bioflavonoids.

Cellular antioxidants for instant SOD, POD, CAT, QR, GST, GSH, γ-GT, GPx and GR are greatly inspected for their substantial function in body's defense system. Superoxide dismutase is a core antioxidant enzyme that governs the dismutation of superoxides to H~2~O~2~ and O~2~. While, catalase is a general enzyme mainly rich in liver, promote transformation of hydrogen peroxide (H~2~O~2~) to water. However, in GSH (glutathione) reaction system, GSH is oxidized to GSSG by the assistance of GPx which sequentially renewed to GSH by the reducing ability of GR. GSH also act as a cofactor for GST that exist equitability in both cytosol and endoplasmic reticulum, chiefly implicate in catalyzing the assembly of GSH electrophile conjugate, therefore decontaminate xenobiotics to create stable compounds \[[@CR48]\]. Lipids peroxidation leads to genetic upregulation of fibrogenic cytokines by instigating the creation of collagen and stimulating hepatic stellate cells \[[@CR49]\]. Administration of DOX results in a momentous escalation in lipid peroxidation revealed by boosting liver tissue MDA, NO and H~2~O~2~ concentrations while drop in tissue antioxidant enzymes, ratifying oxidative stress. These findings are concurrent with previous finding of Liu et al. reported that adriamycin treatment diminished glutathione peroxidase activity and augmented lipid peroxidation \[[@CR50]\]. In our study tissue protein quantity and the amount of oxidative stress markers returned towards normal control with AHE usage. AHE co-treatment results in significant reversal of DOX induced deteriorations in a concentration dependent mode. Analogous findings were also presented in the study of Raskovic and colleagues while investigating the protective effect of silymarin against DOX induced hepatotoxicity \[[@CR41]\]. The main constituents in AHE i.e., 7-*O-*galloyl catechin, catechin, gallic acid and methyl gallate might be responsible for the antioxidant and hepatoprotective influence of AHE \[[@CR16], [@CR17], [@CR20], [@CR22]\]. Previous studies confirm the benefits of these compounds in animal models of hepatotoxicity. Rudolfová and colleagues shown that catechin administration during DOX therapy seems to be safe and beneficial, since EGCG does not reduce DOX anticancer efficacy while augment hepatocytes viability could ameliorate DOX hepatotoxicity \[[@CR51]\]. Another study revealed that vitamin E and catechin can reduce the toxic effects of DOX in liver by ameliorating the action of key enzymes contributing in free radical metabolism, i.e., superoxide dismutase, glutathione peroxidase (GSHPx), catalase (CAT) and malondialdehyde (MDA) in the hepatic tissues of DOX-treated rats. Electron microscopic inspections reinforced biochemical outcomes \[[@CR4]\]. Gallic acid extraordinarily perfected the disruption of liver tissue architecture instigated by *N*-nitrosodiethylamine intoxication as demonstrated by histopathological examination. The hepato-carcinogenic effect of *N*-nitrosodiethylamine can be abrogated by gallic acid usage on the behalf of its exceptional bioactivities including antioxidant, anti-inflammatory, apoptotic, and antitumor effects \[[@CR52]\] .

The histopathological examination is an unambiguous technique for appraising the scavenging potential of the test samples, also to link the outcomes of serum and tissue enzyme assays with morphological alterations. Noteworthy alterations in liver function tests (LFTs) invincibly epitomize the histological confirmation liver fibrosis. Fibrosis do not merely disrupts the regular structural configuration, but also interferes with the flow of blood to preclude the distribution of nutrients to liver tissue \[[@CR53]\]. Liver histology of DOX inoculated groups indicated clear histopathological variations in lymphocyte and kupffer cells, dissolution of hepatic cords, which give the effect of vacuoles aligned by strands of necrotic hepatocytes, nuclear disintegration, vacuolar degenerations, apoptotic cell death, fibrosis and collagen deposition in some areas. Hepatic tissue of AHE treated groups exhibited reduced necrosis, slight inflammatory cells without impairment of cell membrane, low fatty degenerations, cytoplasmic vacuolization, and lessened lobular necrosis around the central vein exhibit degree of safeguarding offered by AHE treatment. AHE provide significant protection against DOX persuaded histoarchitecture alteration in a dose dependent mode.co-treatment at 400 mg/kg b.w. dose was comparable to silymarin treatment groups illuminating its potential equality to silymarin for safeguarding against DOX induced hepatic damage. Hence similar to silymarin, the mechanism of hepatic-protection by AHE might be owing to the antioxidant and free radical quenching potential of *A. hydaspica* \[[@CR42]\]. Thus, AHE might be a potential candidate in recipe with chemotherapy for precluding side effects due to its antioxidant prospective.

Limitations of the study {#Sec35}
------------------------

Before saying a certain remark regarding the likelihood of AHE as an adjuvant to DOX prescription; further investigations are essential to carry out in order to elucidate the exact mechanism at the molecular level. For this, western blot analysis and immunohistochemistry could provide evidence about the effect of AHE on the signaling pathway involved in the pathogenesis of liver damage. Additionally, the influence of AHE on cancer models will provide knowledge on whether the extract affects the anticancer ability of DOX or not.

Conclusion {#Sec36}
==========

By our knowledge, this is the first scientific investigation indicating the protective effect of *Acacia specie* on DOX induced hepatotoxicity in rats. AHE may be a beneficial agent against DOX-induced hepatic harm caused by oxidative stress. Amelioration of LFTs, lipid profile, and oxidative stress markers to adjacent increase in numerous antioxidant enzymes specifies that AHE is able to protect various pathological conditions including; oxidative stress and dyslipidemia. The observed defensive prospective might be attributed to the occurrence of antioxidant compounds in AHE which act in synergism to protect DOX induced oxidative stress. However, it warrants more investigations to divulge the precise mechanism by which *A. hydaspica* mediates its therapeutic action so it can be used as therapy for various other related diseases.
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